KalVista Pharmaceuticals ... (KALV)
NASDAQ: KALV
· Real-Time Price · USD
12.89
-0.06 (-0.46%)
At close: Aug 15, 2025, 3:59 PM
13.13
1.82%
After-hours: Aug 15, 2025, 07:39 PM EDT
KalVista Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
May - April.
| Fiscal Year | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 | Jul 31, 2023 | Apr 30, 2023 | Jan 31, 2023 | Oct 31, 2022 | Jul 31, 2022 | Apr 30, 2022 | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 | Jan 31, 2021 | Oct 31, 2020 | Jul 31, 2020 |
Revenue | n/a | 1.21M | 1.21M | 1.21M | 1.21M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 12.69M | 12.69M | 12.69M | 12.69M | 3.82M | 5.4M | 9.32M |
Cost of Revenue | -224K | 219K | 426K | 623K | 822K | 927K | 929K | 924K | 18.91M | 18.77M | 18.56M | 18.37M | 182K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 224K | 987K | 780K | 583K | 384K | -927K | -929K | -924K | -18.91M | -18.77M | -18.56M | -18.37M | -182K | 12.69M | 12.69M | 12.69M | 12.69M | 3.82M | 5.4M | 9.32M |
Operating Income | -188M | -181.42M | -171.63M | -155.57M | -140.44M | -123.72M | -117.51M | -113.65M | -110.87M | -105.95M | -105.69M | -103.41M | -96.61M | -87.84M | -73.82M | -63M | -57.92M | -48.84M | -48.91M | -45.41M |
Interest Income | 6.43M | 5.96M | 5.25M | 4.67M | 3.9M | 3.19M | 3.24M | 2.91M | 2.23M | 1.69M | 1.22M | 1.06M | 1.09M | 1.14M | 1.01M | 918K | 903K | 952K | 1.19M | 1.5M |
Pretax Income | -180.05M | -171.62M | -156.39M | -141.77M | -126.64M | -108.3M | -100.58M | -95.18M | -92.91M | -90.72M | -91.88M | -89.27M | -82.34M | -73.18M | -60.76M | -51.54M | -46.24M | -38M | -37.24M | -32.72M |
Net Income | -183.44M | -175.87M | -156.39M | -141.77M | -126.64M | -122.03M | -107.33M | -98.18M | -95.91M | -78.03M | -86.16M | -87.31M | -80.38M | -73.18M | -60.76M | -51.54M | -46.24M | -37.87M | -37.12M | -32.59M |
Selling & General & Admin | 116.29M | 100.36M | 80.43M | 61.89M | 54.07M | 38.64M | 35.1M | 32.25M | 30.59M | 30.42M | 30.48M | 28.73M | 26.45M | 25.01M | 21.63M | 19.2M | 16.64M | 13.77M | 13.28M | 13.06M |
Research & Development | 71.71M | 81.07M | 91M | 93.47M | 86.17M | 84.87M | 82.41M | 81.4M | 80.28M | 75.54M | 75.21M | 74.68M | 70.17M | 62.83M | 52.19M | 43.79M | 41.29M | 38.9M | 41.03M | 41.67M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 4.29M | 4.29M | 4.29M | 7.84M | 3.55M | 3.55M | 3.55M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 188M | 181.2M | 171.21M | 155.14M | 140.02M | 123.51M | 117.51M | 113.65M | 110.87M | 105.95M | 105.69M | 103.41M | 96.61M | 87.84M | 73.82M | 63M | 57.92M | 52.66M | 54.31M | 54.73M |
Interest Expense | 5.79M | 2.84M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | -207K | -207K | -207K | -207K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 188M | 181.42M | 171.63M | 155.57M | 140.44M | 123.72M | 117.51M | 113.65M | 110.87M | 105.95M | 105.69M | 103.41M | 96.61M | 87.84M | 73.82M | 63M | 57.92M | 52.66M | 54.31M | 54.73M |
Income Tax Expense | 3.39M | 5.1M | 856K | 856K | 856K | 13.73M | 6.76M | 3M | 3M | -12.69M | -5.72M | -1.96M | -1.96M | -3.53M | -3.53M | -3.53M | -3.53M | -124K | -124K | -124K |
Shares Outstanding (Basic) | 49.65M | 52.64M | 46.7M | 46.23M | 43.59M | 34.72M | 34.57M | 34.41M | 34.34M | 28.28M | 24.6M | 24.56M | 24.54M | 24.48M | 24.44M | 24.43M | 22.66M | 17.96M | 17.91M | 17.85M |
Shares Outstanding (Diluted) | 49.65M | 52.64M | 46.7M | 46.23M | 43.59M | 34.72M | 34.57M | 34.41M | 34.34M | 28.28M | 24.6M | 24.56M | 24.55M | 24.48M | 24.44M | 24.43M | 23.12M | 17.96M | 17.91M | 17.85M |
EPS (Basic) | -3.69 | -3.72 | -3.64 | -3.53 | -3.4 | -3.55 | -3.22 | -3.17 | -3.37 | -3.1 | -3.51 | -3.56 | -3.28 | -3.04 | -2.68 | -2.46 | -2.41 | -2.12 | -2.08 | -1.83 |
EPS (Diluted) | -3.69 | -3.72 | -3.64 | -3.53 | -3.4 | -3.55 | -3.22 | -3.17 | -3.37 | -3.1 | -3.51 | -3.56 | -3.28 | -3.03 | -2.67 | -2.45 | -2.4 | -2.12 | -2.08 | -1.83 |
EBITDA | -173.33M | -175.2M | -166.95M | -150.91M | -135.82M | -122.93M | -116.73M | -112.9M | -110.15M | -105.27M | -105.06M | -102.82M | -96.05M | -87.3M | -73.28M | -62.45M | -57.39M | -48.31M | -48.38M | -44.89M |
EBIT | -174.27M | -176.1M | -167.83M | -151.76M | -136.64M | -123.72M | -117.51M | -113.65M | -110.87M | -105.95M | -105.69M | -103.41M | -96.61M | -87.84M | -73.82M | -63M | -57.92M | -48.84M | -48.91M | -45.41M |
Depreciation & Amortization | 941K | 899K | 877K | 847K | 822K | 927K | 929K | 924K | 883K | 1.57M | 1.51M | 1.44M | 1.42M | 548K | 535K | 541K | 537K | 109K | 252K | 381K |